From Nasdaq, Inc.:

The European Commission has approved Pfizer Inc.’s Talzenna, an oral PARP inhibitor, in combination with Xtandi, for the treatment of adult patients with metastatic castration-resistant prostate cancer in whom chemotherapy is not clinically indicated. This approval makes Talzenna the first and only PARP inhibitor licensed in the European Union for use with Xtandi for this indication. The approval is valid in all 27 EU member states plus Iceland, Liechtenstein, and Norway. Talzenna in combination with Xtandi was also approved by the FDA for the treatment of adult patients with HRR gene-mutated mCRPC in June 2023. Pfizer has shared the TALAPRO-2 data with other regulatory agencies to support regulatory filings. For More Such Health News, visit rttnews.com.



Read more: EU Approves Pfizer’s Talzenna Combination To Treat Metastatic Castration-resistant Prostate Cancer